BJMO - volume 12, issue 1, february 2018
A. Van Goethem PhD, J. Vandesompele , T. Van Maerken MD, PhD
Neuroblastoma is a rare developmental tumour of young children accounting for a disproportionally high proportion of paediatric cancer deaths. Increasing insights into neuroblastoma genetics and biology led to the identification of the MDM2 antagonist idasanutlin as a promising therapeutic strategy. In this thesis, we investigated two key aspects that could facilitate the clinical implementation of idasanutlin for the treatment of neuroblastoma patients. First, we identified the BCL2 inhibitor venetoclax as a synergistic drug partner of idasanutlin using both in vitro and in vivo model systems of neuroblastoma. Second, we discovered circulating miRNAs that dynamically respond to p53 activation in mice carrying human neuroblastoma xenografts; opening up possibilities for non-invasive treatment monitoring.
(BELG J MED ONCOL 2018;12(1):26–28)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
